NASDAQ:EPZM - Epizyme Stock Price, Forecast & News

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

Epizyme Inc (NASDAQ:EPZM) posted its earnings results on Wednesday, October, 30th. The biopharmaceutical company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.51) by $0.11. The biopharmaceutical company earned $5.72 million during the quarter, compared to the consensus estimate of $5.50 million. Epizyme had a negative return on equity of 49.38% and a negative net margin of 468.53%. View Epizyme's Earnings History.

Epizyme is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Epizyme.

Epizyme will be holding an earnings conference call on Monday, February 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

9 equities research analysts have issued 12-month target prices for Epizyme's shares. Their forecasts range from $18.00 to $36.00. On average, they expect Epizyme's share price to reach $27.14 in the next twelve months. This suggests a possible upside of 7.8% from the stock's current price. View Analyst Price Targets for Epizyme.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Epizyme.

Media coverage about EPZM stock has trended neutral recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Epizyme earned a media sentiment score of 0.5 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Epizyme.

Epizyme saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 8,780,000 shares, an increase of 9.5% from the December 31st total of 8,020,000 shares. Based on an average daily volume of 919,900 shares, the days-to-cover ratio is presently 9.5 days. Approximately 11.5% of the company's stock are short sold. View Epizyme's Current Options Chain.

Some companies that are related to Epizyme include Sarepta Therapeutics (SRPT), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Ascendis Pharma A/S (ASND), Reata Pharmaceuticals (RETA), The Medicines (MDCO), Horizon Therapeutics (HZNP), Amarin (AMRN), United Therapeutics (UTHR), Global Blood Therapeutics (GBT) and Evotec (EVTCY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Epizyme investors own include Amarin (AMRN), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Clovis Oncology (CLVS), TG Therapeutics (TGTX), Verastem (VSTM), Crispr Therapeutics (CRSP), Exelixis (EXEL), Gilead Sciences (GILD) and Intercept Pharmaceuticals (ICPT).

Epizyme's stock is owned by many different of institutional and retail investors. Top institutional investors include Palo Alto Investors LP (6.75%), Victory Capital Management Inc. (2.91%), Victory Capital Management Inc. (2.73%), State Street Corp (2.71%), FMR LLC (2.45%) and Loomis Sayles & Co. L P (1.76%). Company insiders that own Epizyme stock include David M Mott, Matthew Ros, Robert B Bazemore and Shefali Agarwal. View Institutional Ownership Trends for Epizyme.

EPZM stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management II LLC, FMR LLC, State Street Corp, Palo Alto Investors LP, UBS Group AG, Rafferty Asset Management LLC, Goldman Sachs Group Inc. and Citigroup Inc.. Company insiders that have sold Epizyme company stock in the last year include David M Mott, Matthew Ros, Robert B Bazemore and Shefali Agarwal. View Insider Buying and Selling for Epizyme.

EPZM stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Victory Capital Management Inc., Victory Capital Management Inc., State of New Jersey Common Pension Fund D, Candriam Luxembourg S.C.A., Delta Investment Management LLC, EAM Investors LLC and First Trust Advisors LP. View Insider Buying and Selling for Epizyme.

Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EPZM stock can currently be purchased for approximately $25.18.

Epizyme has a market capitalization of $2.29 billion and generates $21.70 million in revenue each year. The biopharmaceutical company earns $-123,630,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Epizyme employs 124 workers across the globe.View Additional Information About Epizyme.

The official website for Epizyme is http://www.epizyme.com/.

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]